|
摘要：
|
|
摘要：乙型肝炎病毒（hepatitis B virus，HBV）感染严重危害人类健康，一线核苷
（酸）类似物 [nucleos(t)ide analogues，NAs] 抗病毒治疗是目前临床广泛使用的有
效治疗措施之一，但恩替卡韦（entecavir，ETV）/替诺福韦酯（tenofovir disoproxil
fumarate，TDF）应答不佳降低了抗病毒治疗有效率。目前应答不佳评估标准尚未形
成统一共识，亦缺乏明确的流行病学资料，对于应答不佳的原因、危害有待进一步研
究，治疗策略仍有待验证。本文主要就ETV/TDF应答不佳的评估标准、原因、危害及
NAs治疗方案进行综述。
|
|
Abstract: Hepatitis B virus (HBV) infection is severely threatening human health. Antiviral
therapy with first-line nucleos(t)ide analogues (NAs) is one of the effective treatments, but
suboptimal responses to entecavir (ETV) and tenofovir disoproxil fumarate (TDF) reduce the
effective rate of antiviral therapy. There is no consensus on evaluation criteria for suboptimal
response, and epidemiological data is scarce at present. The causes and harms of suboptimal
response need to be furtherly investigated and treatment strategies still need to be verified.
This review aimed to introduce the evaluation criteria, causes, harms and therapeutic regimen
of NAs for suboptimal response to ETV and TDF.
|
|
基金项目：
|
|
|
|
作者简介：
|
|
|
|
参考文献：
|
|
|
|
服务与反馈：
|
|
【文章下载】【加入收藏】
|
|
|
|